Skip to main content

Ultrase MT 18 Side Effects

Generic name: pancrelipase

Medically reviewed by Last updated on Feb 12, 2024.

Note: This document contains side effect information about pancrelipase. Some dosage forms listed on this page may not apply to the brand name Ultrase MT 18.

Applies to pancrelipase: oral capsule, oral capsule delayed release, oral tablet, oral tablet enteric coated. Other dosage forms:

Serious side effects of Ultrase MT 18

Along with its needed effects, pancrelipase (the active ingredient contained in Ultrase MT 18) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking pancrelipase:


With high doses

With very high doses

With powder dosage form or powder from opened capsules

- if breathed in

With tablets

- if held in the mouth

Incidence not known

Other side effects of Ultrase MT 18

Some side effects of pancrelipase may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

Incidence not known

For Healthcare Professionals

Applies to pancrelipase: oral capsule, oral capsule extended release, oral delayed release capsule, oral powder for reconstitution, oral tablet, oral tablet extended release.


The most commonly reported side effects included gastrointestinal complaints, abdominal pain, and headaches.[Ref]


Very common (10% or more): Gastrointestinal complaints (up to 55%), abdominal pain (up to 18%), vomiting (up to 12%)

Common (1% to 10%): Abdominal discomfort, abdominal distention, abdominal pain upper, abdominal tenderness, abnormal feces, anal pruritus, ascites, constipation, diarrhea, dyspepsia, early satiety, flatulence, frequent bowel movements, nausea

Uncommon (0.1% to 1%): Bowel stricture formation

Frequency not reported: Duodenitis, fibrosing colonopathy, gastritis, steatorrhea, strictures of the ileocecum

Postmarketing reports: Distal intestinal obstruction syndrome (DIOS)[Ref]

Bowel stricture formation occasionally occurred in children with cystic fibrosis who received high doses.

Moderate duodenitis and gastritis occurred in a patient with exocrine pancreatic insufficiency due to cystic fibrosis 16 days after completing treatment with 4000 lipase units/gram fat ingested per day for 5 to 6 days, followed by placebo for an additional 5 to 6 days.[Ref]

Nervous system

A dull headache was reported by a patient receiving treatment with ursodeoxycholic acid concomitantly. The event resolved without sequelae after discontinuation of this drug.[Ref]

Very common (10% or more): Headache (up to 15%)

Common (1% to 10%): Dizziness

Postmarketing reports: Dull headache[Ref]


Common (1% to 10%): Blood cholesterol decreased, blood glucose increased, decreased appetite, diabetes mellitus, diabetes mellitus including subtypes, hyperglycemia, hypoglycemia, weight decreased

Frequency not reported: Hyperuricemia[Ref]


Common (1% to 10%): ALT increased, AST increased, biliary tract stones, blood alkaline phosphatase increased, cholangitis, GGT increased, hydrocholecystis

Postmarketing reports: Asymptomatic liver enzyme elevations[Ref]


Common (1% to 10%): Anemia, hematocrit, hemoglobin, red blood cell count, increased white blood cell count

Frequency not reported: Transient neutropenia with/without clinical sequelae[Ref]


Common (1% to 10%): Bronchitis, cough, nasopharyngitis, oropharyngeal pain, respiratory tract infection

Postmarketing reports: Asthma[Ref]


Common (1% to 10%): Asthenia, malaise, pain, pyrexia

Frequency not reported: Fatigue[Ref]


Common (1% to 10%): Pruritus, rash, skin reactions

Frequency not reported: Itching, urticaria/hives

Postmarketing reports: Blotchy/red facial rash[Ref]


Common (1% to 10%): Arthralgia, back pain, musculoskeletal pain

Postmarketing reports: Muscle spasm, myalgia[Ref]


Common (1% to 10%): Contusion, hypertension, peripheral edema[Ref]


Common (1% to 10%): Metastases to specific sites, recurrent pancreatic carcinoma

Postmarketing reports: Recurrence of preexisting carcinoma[Ref]


Common (1% to 10%): Insomnia, irritability[Ref]


Common (1% to 10%): Renal cyst[Ref]


Common (1% to 10%): Viral infection[Ref]


A patient with a known history of allergy to another pancrelipase (the active ingredient contained in Ultrase MT 18) product developed a mild allergic reaction, including red, blotchy facial rash and itching. The event resolved without sequelae after discontinuation of this drug.[Ref]

Frequency not reported: Anaphylactic reactions, hypersensitivity

Postmarketing reports: Anaphylaxis, mild allergic reactions, severe allergic reactions[Ref]


Frequency not reported: Hyperuricosuria[Ref]


Postmarketing reports: Blurred vision[Ref]

Frequently asked questions


1. (2001) "Product Information. Viokase (pancrelipase)." Wyeth-Ayerst Laboratories

2. (2022) "Product Information. Ku-Zyme (pancrelipase)." Schwarz Pharma

3. (2001) "Product Information. Zymase (pancrelipase)." Organon

4. (2001) "Product Information. Cotazym (pancrelipase)." Organon

5. (2001) "Product Information. Cotazym-S (pancrelipase)." Organon

6. (2001) "Product Information. Pancrease (pancrelipase)." McNeil Pharmaceutical

7. (2022) "Product Information. Pancrease (pancrelipase)." Apothecon Inc

8. (2001) "Product Information. Ultrase (pancrelipase)." Scandipharm Inc

9. "Product Information. Ultrase MT 12 (pancrelipase)." Scandipharm Inc

10. (2001) "Product Information. Creon 5 (pancrelipase)." Solvay Pharmaceuticals Inc

11. (2001) "Product Information. Creon 10 (pancrelipase)." Solvay Pharmaceuticals Inc

12. (2001) "Product Information. Creon 20 (pancrelipase)." Solvay Pharmaceuticals Inc

13. Cerner Multum, Inc. "Australian Product Information."

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.